Neuroendocrine tumors and pregnancy: the French PregNET study
Authors' conclusion
Pregnancy is generally safe and successful in women with NETs. No major safety concerns were observed with SSA; however, these findings should be interpreted cautiously given the small sample size. Their use should remain individualized within a multidisciplinary approach, with early postpartum tumor assessment to optimize fetal and maternal outcomes.
Study context
- Population
- Women with neuroendocrine tumors (NETs) who experienced pregnancy, French GTE and RENATEN-ENDOCAN networks; median maternal age at first pregnancy 31
- Participants
- 17 women26 pregnancies27 births
- Outcome
- Postpartum tumor evolution (mRECIST on CT at 1 and 6 months after delivery)
- Follow-up
- 1 and 6 months postpartum
Methodological detailsnational, multicentre
- National
- Multicentre
Main finding
As reported in the abstract
Resected localized NETs: remained in remission post-pregnancy
71.4%
Resected localized NETs: recurrence
28.6%
Metastatic NETs: stable disease
50%
Metastatic NETs: progression
21.4%
Observational data: associations, not effects.
Further findings
Carcinoid syndrome symptoms
- No worsening of carcinoid syndrome symptoms
Cesarean rate
- Overall cesarean rate
- 16.7%
- Cesarean rate with carcinoid syndrome
- 25%
Live birth rate
- Under surveillance
- 94.4%
- Under SSA therapy
- 91%
Fetal growth and development
- Intrauterine growth restriction rate higher with SSA therapy
- Birth weight and length not affected
- No developmental issues by age 2
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →